Trial Profile
Phase II Study Investigating the Toxicity and Efficacy of Single Agent Temsirolimus (Torisel) in Chemotherapy-naive Castration-Resistant Prostate Cancer Patients.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Temsirolimus (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- 28 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 May 2013 Planned end date changed from 1 Jun 2015 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 24 May 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.